| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [2] |
Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers[J]. Cancer Discov, 2017, 7(9):943-962.
|
| [3] |
Park K, Kim KP, Park S, et al. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer[J]. Asia Pac J Clin Oncol, 2017, 13(1):13-20.
|
| [4] |
Morizane C, Ueno M, Ikeda M, et al. New developments in systemic therapy for advanced biliary tract cancer[J]. Jpn J Clin Oncol, 2018, 48(8):703-711.
|
| [5] |
任正刚．肝细胞癌的免疫治疗[J]．临床肝胆病杂志，2018, 34(7):1371-1373.
|
| [6] |
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet, 2015, 47(9):1003-1010.
|
| [7] |
Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma[J]. Clin Cancer Res, 2016, 22(2): 470-478.
|
| [8] |
Gou M, Zhang Y, Si H, et al. Efficacy and safety of nivolumab for metastatic biliary tract cancer[J]. Onco Targets Ther, 2019(12):861-867.
|
| [9] |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349):409-413.
|
| [10] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
|
| [11] |
Czink E, Kloor M, Goeppert B, et al. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J]. Cold Spring Harb Mol Case Stud, 2017, 3(5): pii: a001974.
|
| [12] |
Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma[J]. Oncotarget, 2017, 8(15):24644-24651.
|
| [13] |
Wang Y, Ding M, Zhang Q, et al. Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis[J]. J Cancer, 2017, 8(1):74-84.
|
| [14] |
Liu WM, Fowler DW, Smith P, et al. Pretreatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses[J]. Br J Cancer, 2010, 102(1):115-123.
|
| [15] |
Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice[J]. J Clin Invest, 2011, 121(8):3100-3108.
|
| [16] |
McLoughlin KC, Brown ZJ, Shukla Y, et al. Promise and pitfalls of immune checkpoint inhibitors in hepato-pancreato-biliary malignancies[J]. Discov Med, 2018, 26(142):85-92.
|
| [17] |
Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-Label, phase I trial (JVDF)[J]. Oncologist, 2018, 23(12): 1407-e136.
|